Toshiharu Morikawa

11PUBLICATIONS
23CO-AUTHORS
Haematological tumoursCancer therapy (excl. chemotherapy and radiation therapy)Tumour immunologyPredictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (11)

|Jul 01, 2026
Elevation of Eosinophil Proportion After Pembrolizumab Increases the Risk of Immune-Related Adverse Events in Patients With Bladder Cancer.

|May 04, 2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.

|Mar 26, 2026
Enhanced magnetic hyperthermia using anti-PD-L1 antibody-conjugated magnetoliposomes in a murine subcutaneous bladder cancer model.

Masakazu Gonda, Noriyasu Kawai, Daiki Ishikawa

|Jan 30, 2026
Evaluation of the Safety of Robot-Assisted Radical Cystectomy for Bladder Cancer in Octogenarians.

Toshiharu Morikawa, Shuzo Hamamoto, Yoshihiko Tasaki

|Jan 05, 2026
Establishment of a Patient-Derived Xenograft Model of a Testicular Yolk Sac Tumor.

Nobuhiko Shimizu, Taku Naiki, Aya Naiki-Ito

|Jan 03, 2025
Efficacy of pembrolizumab plus lenvatinib as first-line treatment for metastatic renal cell carcinoma with multiple brain metastases.

Daisuke Matsumoto, Taku Naiki, Aya Naiki-Ito

Pageof 2

Frequent Collaborators

10 joint publications

Taku Naiki

9 joint publications

Takahiro Yasui

5 joint publications

Shuzo Hamamoto

5 joint publications

Yosuke Sugiyama